Aurinia Pharmaceuticals AUPH Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $41.01M-38.3% | $80.21M-3.9% | $73.19M+97.1% | $53M+58.7% | $66.43M+3.1% | ||
| $49.18M+21.9% | $41.45M+13.4% | $30.73M-15.8% | $40.09M+57.1% | $40.35M+39.6% | ||
| $183.4M+12.5% | $183.18M+17.0% | $176.72M+12.5% | $170.64M+12.9% | $162.99M+12.1% | ||
| $480.24M+18.4% | $491.97M+10.2% | $438.74M-0.4% | $408.97M-0.2% | $405.76M+1.9% | ||
| $1.99M-22.9% | $2.11M-22.7% | $2.27M-21.5% | $2.42M-20.4% | $2.58M-19.4% | ||
| $3.59M-13.7% | $3.76M-13.6% | $3.9M-13.5% | $4.05M-12.4% | $4.16M-12.6% | ||
| $724M+43.4% | $751.59M+36.5% | $527.53M-4.0% | $502.56M-4.0% | $504.85M-2.3% | ||
| $2.66M-36.9% | $3.31M-36.1% | $2.21M-75.1% | $3.31M-60.6% | $4.22M-25.6% | ||
| $5.04M+9.6% | $3.72M-66.2% | $4.6M+6.9% | $5.5M+25.9% | $4.59M-6.4% | ||
| $16.52M+13.9% | $16.52M+17.6% | $16.31M+9.3% | $16.17M+16.3% | $14.51M+5.7% | ||
| $86.56M+26.5% | $93.72M-4.1% | $76.22M-3.0% | $78.27M+1.8% | $68.41M-3.7% | ||
| $156.37M+1.1% | $170.26M-1.7% | $161.76M+0.2% | $167.26M+5.3% | $154.66M-1.6% | ||
| $1.09B-6.6% | $1.12B-5.7% | $1.12B-7.4% | $1.12B-6.9% | $1.16B-3.7% | ||
| -$615.01M+32.7% | -$649.37M+30.7% | -$860.16M+8.3% | -$891.71M+6.4% | -$913.23M+4.2% | ||
| $567.63M+62.1% | $581.33M+54.0% | $365.77M-5.7% | $335.3M-8.0% | $350.19M-2.6% | ||
| $724M+43.4% | $751.59M+36.5% | $527.53M-4.0% | $502.56M-4.0% | $504.85M-2.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Aurinia Pharmaceuticals cover its short-term obligations?
- Its current ratio is 5.55 — current assets exceed current liabilities.
- Where does Aurinia Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.